Efficacy and safety of recombinant human activated protein C for severe sepsis
Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine. 2001;344(10):699–709.
A randomized, double-blind, placebo-controlled, multicenter trial showing that treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.
|
This item has not yet been rated
|
 |
View article abstract
|
